Amneal touts results from Phase III trial in Parkinson's; NovaRock partners on cancer drug
Amneal Pharmaceuticals announced positive results yesterday from a pivotal Phase III clinical trial that evaluated IPX-203 in patients with Parkinson’s disease who have motor fluctuations.
The trial met its primary endpoint, demonstrating superior “Good On” time — time without dyskinesia — from baseline in hours per day at the end of the 13-week double-blinded treatment period with IPX-203, an extended-release formulation of carbidopa/levodopa. The drug data was compared with immediate-release carbidopa/levodopa.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.